Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2017-01-09 M&A Activity
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
M&A Activity Classification · 99% confidence The document is a press release dated January 9, 2017, announcing that Ipsen has entered into a definitive agreement to acquire oncology assets, specifically the commercial rights to Onivyde®, from Merrimack Pharmaceuticals. The text details the financial terms ($575 million upfront plus milestones), the strategic rationale (strengthening Ipsen's oncology presence in the US), and includes forward-looking statements and details about a conference call. This type of announcement, detailing a significant corporate transaction (acquisition/merger), strongly aligns with the definition of M&A Activity (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2017-01-09 French
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 98% confidence The document explicitly contains a table detailing 'Aggregated presentation by day and market' showing 'Transaction date', 'Daily total volume (in number of shares)', and 'Daily weighted average price of shares acquired'. The title section clearly states 'Disclosure of transactions in own shares between 26/12/2016 and 30/12/2016'. This content directly relates to the company buying back or dealing in its own shares, which corresponds to the definition for Transaction in Own Shares (POS). It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing report (DIRS), but a report on the company's own share transactions.
2017-01-03 English
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 99% confidence The document text is titled 'Déclaration des transactions sur actions propres réalisées du 26/12/2016 au 30/12/2016' (Declaration of own share transactions carried out from 12/26/2016 to 12/30/2016) and contains a detailed table showing daily transaction volumes and weighted average prices for shares. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares (share repurchase/issuance). This matches Filing Type Code: POS (Transaction in Own Shares).
2017-01-03 French
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 98% confidence The document explicitly details 'Disclosure of transactions in own shares' over a specific period (19/12/2016 to 23/12/2016) and presents aggregated data on volume and price for these transactions. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The relevant code is POS.
2016-12-27 English
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 99% confidence The document is titled "Déclaration des transactions sur actions propres réalisées du 19/12/2016 au 23/12/2016" (Declaration of transactions on own shares carried out from 12/19/2016 to 12/23/2016). It contains detailed tables showing daily transaction volumes, weighted average prices, and markets for shares of IPSEN. This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares (share repurchase/issuance). This matches the 'Transaction in Own Shares' category (POS).
2016-12-27 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 95% confidence The document is a press release dated December 21, 2016, announcing an amendment to an exclusive license agreement between Exelixis and Ipsen regarding the commercialization and development of cabozantinib in Canada. It details financial considerations (initial payment, milestones, royalties) and strategic updates related to the drug's approvals and launch in the US and Europe. This type of announcement, which details corporate agreements, financing terms, and strategic business developments, fits best under the 'Capital/Financing Update' category (CAP) as it involves significant financial terms and rights transfer, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. However, given the focus on the financial structure of the expanded licensing deal, CAP is a strong candidate. It is not a formal regulatory report (10-K, IR, ER, MRQ), nor is it a management change (MANG) or a dividend notice (DIV). Since it details a significant financial transaction involving licensing rights and payments, 'CAP' (Capital/Financing Update) is the most appropriate classification, although 'RNS' is a possibility for general corporate news. Given the explicit mention of a $10 million initial payment and potential milestone payments, CAP is preferred over the general RNS.
2016-12-21 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.